scholarly journals A Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer

2017 ◽  
Vol 8 (3) ◽  
pp. 71-75 ◽  
Author(s):  
Hui Hu ◽  
Wei Wei ◽  
Xin Yi ◽  
Ling Xin ◽  
Yinhua Liu
Keyword(s):  
Breast Cancer ◽  
Retrospective Analysis ◽  
Clinical Utility ◽  
Staging System ◽  
Cancer Staging ◽  
8Th Edition

scholarly journals Impact of biomarkers and genetic profiling on breast cancer prognostication: A comparative analysis of the 8th edition of breast cancer staging system

2019 ◽  
Vol 25 (5) ◽  
pp. 829-837 ◽  
Author(s):  
Esther C. Yoon ◽  
Christopher Schwartz ◽  
Edi Brogi ◽  
Katia Ventura ◽  
Hannah Wen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Comparative Analysis ◽  
Staging System ◽  
Cancer Staging ◽  
Genetic Profiling ◽  
Breast Cancer Staging ◽  
8Th Edition

Prognostic impact of the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system on clinically negative lymph nodes (cN0) breast cancer patients

2020 ◽  
Vol 26 (7) ◽  
pp. 1265-1269 ◽  
Author(s):  
Augusto Lombardi ◽  
Valeria Vitale ◽  
Giuseppe Nigri ◽  
Carlotta Olivieri ◽  
Maria Rosaria Mastrangeli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Staging System ◽  
Cancer Staging ◽  
Prognostic Impact ◽  
Breast Cancer Patients ◽  
American Joint Committee ◽  
Negative Lymph Nodes ◽  
8Th Edition

Comparing the American Joint Committee on Cancer (AJCC) breast cancer staging eighth versus seventh edition and breast cancer biology in large databases.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e12077-e12077
Author(s):  
Jessica S. Young ◽  
Kazuaki Takabe ◽  
Mariko Asaoka ◽  
Stephen B. Edge
Keyword(s):  
Breast Cancer ◽  
Cancer Biology ◽  
Staging System ◽  
Cancer Staging ◽  
Gene Set Enrichment Analysis ◽  
Breast Cancer Staging ◽  
7Th Edition ◽  
Stage 1 ◽  
8Th Edition ◽  
Better Than

e12077 Background: The AJCC 8th edition Breast Cancer Staging system includes biomarkers (estrogen receptor, progesterone receptor, Her2), grade and a genomic assay, to better reflect outcomes, compared to the 7th edition. We used databases with anatomic, biomarker and genomic information to determine if the 8th edition reflects biology better than the 7th edition. Methods: 696 breast cancer patients in The Cancer Genome Atlas (TCGA) and Text Information Extraction System (TIES) were staged both with 7th and 8th edition. Results: From the 7th to 8th editions, 66% of stage 2 patients migrated (64% to stage 1, 1.5% to stage 3). 36% of stage 3 patients migrated (22% to stage 1, 13% to stage 2). We analyzed the differences between stage 1 and 2 in both editions, and the overall survival hazard ratio calculated using Cox regression was greater in the 8th edition than the 7th (HR=1.50, HR=1.22 respectively). We performed Gene Set Enrichment Analysis (GSEA) and found that gene sets related to cell cycle and cell proliferation (E2F targets, G2M checkpoint) were significantly enriched in higher stage in 8th edition but not 7th. Mutant Allele Tumor Heterogeneity (MATH) and Homologous Recombination Defects (HRD) were elevated in higher stages in the 8th edition (p=0.022, p<0.001 respectively), but not the 7th. Immune cells (CD8 Tcell, NK cell) as well as CYT (Immune cytolytic activity score), and Tcell exhaustion markers (PD1, PDL1) were all found to be elevated in higher stage in 8th edition, but not 7th. Conclusions: The 8th edition AJCC Breast Cancer Staging system categorizes cancers by aggressive biology better than the 7th edition. We also found that higher stage tumors trigger an enhanced immune response, but are unable to overcome the aggressive cancer biology.

scholarly journals The Effect of the New Eighth Edition Breast Cancer Staging System on 100 Consecutive Patients

2019 ◽  
Vol 11 (6) ◽  
pp. 407-414 ◽  
Author(s):  
Ashley Biswal ◽  
Jacqueline Erler ◽  
Omar Qari ◽  
Arthur A. Topilow ◽  
Varsha Gupta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Staging System ◽  
Cancer Staging ◽  
Breast Cancer Staging ◽  
Eighth Edition

scholarly journals A review of the 8th edition of the AJCC staging system for oropharyngeal cancer according to HPV status

2020 ◽  
Vol 277 (9) ◽  
pp. 2407-2412 ◽  
Author(s):  
Piotr Machczyński ◽  
Ewa Majchrzak ◽  
Patryk Niewinski ◽  
Joanna Marchlewska ◽  
Wojciech Golusiński
Keyword(s):  
Oropharyngeal Cancer ◽  
Staging System ◽  
Cancer Staging ◽  
Nodal Metastasis ◽  
Clinical Staging ◽  
Previous Edition ◽  
Hpv Status ◽  
Ajcc Staging System ◽  
Ajcc Staging ◽  
8Th Edition

Abstract Background The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has increased substantially in recent decades, particularly p16-positive human papillomavirus (HPV)-related OPSCC, which has risen by 50% in western countries. HPV-positivity is the most favourable non-anatomic predictor of oropharyngeal cancer outcomes, which underscores the importance of incorporating this variable into the cancer staging system. Methods In the present article, we review the differences between the 7th and 8th editions of the AJCC staging system, with particular focus on the role of HPV-positivity in patients with head and neck cancer. Results In the previous edition (7th edition) of the AJCC/UICC manual, HPV status and its correlation with nodal metastasis were not considered, thereby leading to incorrect lymph node (N) staging and, potentially, inadequate treatment and worse outcomes. The 8th edition of the AJCC manual addresses these issues, providing more accurate discrimination between groups and better risk stratification in patients with HPV-positive OPSCC. In the future, additional adjustments are likely to be needed, such as unification of the pathological and clinical staging models. Conclusions The new staging system is substantially more accurate than the previous system and should be widely adopted in routine clinical practice.

Sign in / Sign up

Export Citation Format

Share Document